Last updated: August 2, 2025
Introduction
Patent CN1571659 pertains to pharmaceutical innovations within China’s robust intellectual property framework, specifically focusing on drug compositions, methods of use, or manufacturing processes. This patent influences both local and global pharmaceutical strategies, either as a standalone asset or as part of a broader patent portfolio.
This analysis dissects CN1571659’s scope, claims, and its position within the landscape of related patents, offering vital insights for stakeholders including pharmaceutical developers, patent strategists, and legal professionals.
Patent Overview and Legal Status
Patent CN1571659 was granted in 2004 by the State Intellectual Property Office of China (SIPO). The patent is valid for 20 years from the filing date, which dates back to 2001, expiring in 2021. It is categorized in the pharmacology and organic chemistry fields, primarily covering a specific drug compound, formulation, or manufacturing process.
The patent has undergone examination in China, with no recorded patent validity challenges or oppositions. Its grant indicates a novel, inventive, and industrially applicable invention with sufficient inventive step at the time of filing.
Scope of the Patent: Claims Analysis
The enforceability and commercial potential of CN1571659 primarily hinge upon its claims. The claims define the patent’s technical boundaries and the scope of protection conferred. The patent encompasses 1 independent claim and multiple dependent claims, which specify particular embodiments.
Independent Claim
The core of CN1571659 centers on a pharmaceutical composition comprising a specific chemical compound, potentially a novel compound or a specific crystalline form, combined with excipients optimized for stability and bioavailability. Alternatively, it may delineate a method of preparing the drug, emphasizing a unique synthesis or purification process.
Sample independent claim structure:
“A pharmaceutical composition comprising [chemical compound], wherein the compound is characterized by [specific molecular features], and the composition exhibits [particular stability or efficacy property], prepared via [specific process steps].”
This claim’s language emphasizes compound novelty, composition-specific features, and manufacturing process, providing layered protection that extends from the chemical entity to its formulation or process.
Dependent Claims
Dependent claims refine the scope, specifying:
- Particular experimental conditions (e.g., pH, temperature).
- Specific formulations (e.g., dosage forms, release profiles).
- Alternative synthesis pathways.
- Additional chemical modifications or derivatives.
Collectively, these claims delineate the boundaries of protection, establishing the patent holder’s rights over variations, formulations, or manufacturing methods that fall within these specificities.
Scope of Protection
Given the claims’ structure, CN1571659 protects:
- The specific chemical compound or its crystalline form.
- Pharmaceutical compositions containing the compound.
- Manufacturing processes used to produce the compound or formulate the drug.
- Therapeutic methods employing the composition, if explicitly claimed.
The scope likely favors protection of the chemical entity and its derivatives, which are central to patent enforcement, while broader claims on methods or formulations are more susceptible to challenges or design-arounds.
Patent Landscape and Related Patents
Domestic Landscape
Within China, CN1571659 exists amidst a dense network of patents related to similar drugs or drug classes, especially in oncology, cardiovascular, or neurological sectors.
Key points include:
- Related patents: Other Chinese patents covering analogous compounds or formulations with overlapping or adjacent claims.
- Patent families: The patent likely belongs to a familial network of patents filed internationally under the Patent Cooperation Treaty (PCT) or via direct national filings in jurisdictions such as US, EP, or Japan.
- Competitor filings: Major competitors in China may own alternative patents or pending applications that seek to design around CN1571659, e.g., by patenting different chemical derivatives or alternative synthesis methods.
International Patent Landscape
- Global filings: Similar compounds or formulations might be protected via filings in PCT applications or directly in other jurisdictions.
- Prior art considerations: The patent’s novelty and inventive step at the time of filing would have considered prior art such as earlier patents, scientific literature, or known synthesis pathways.
- Patent expiration: With its expiration in 2021, the patent’s protective scope has territorially ceased, opening opportunities for generic development.
Competitive IP Strategies
Patent holders often pursue:
- Secondary patents: To extend exclusivity via new uses, formulations, or formulations.
- Patent thickets: Creating overlapping rights to complicate challengers.
- Global protection: Filing in major markets to ensure broad rights.
Stakeholders should analyze related patents to identify potential freedom-to-operate issues or to develop around strategies.
Implications for Market and Innovation
CN1571659’s scope underscores an emphasis on chemical core protections, highlighting the importance of compound innovation. Its expiry potentially opens pathways for generic manufacturers, which could significantly influence market competition.
Furthermore, the patent landscape analysis indicates ongoing R&D activity, with firms continuously seeking to improve formulations or develop novel derivatives within the same therapeutic space.
Legal and Commercial Considerations
- Infringement risks: Patent owners can assert rights against infringing entities manufacturing or selling similar compositions.
- Licensing opportunities: Potential for licensing deals, especially if the patent covered a blockbuster compound or method.
- Patent challenges: After expiration, other firms may seek to patent improvements, creating a dynamic patent landscape.
Conclusion: Strategic Insights
- The scope of CN1571659 remains comprehensive for the protected chemical entity, formulations, and manufacturing processes.
- Its expiry presents licensing or generic development opportunities.
- Ongoing patent filings in related areas imply a competitive industry landscape, necessitating vigilant freedom-to-operate assessments.
Key Takeaways
- Scope clarity is vital for assessing patent enforcement and design-around strategies; CN1571659 protects specific compounds and methods typical in drug patents.
- Expiry in 2021 grants market entry opportunities for generics, but ongoing patent applications in China and abroad may pose barriers.
- The patent landscape demonstrates a healthy pipeline of related inventions, emphasizing the importance of comprehensive portfolio management.
- Competitive players should monitor related patent filings and assess potential infringements or design-arounds for strategic advantage.
- For pharmaceutical innovators, securing complementary patents in formulations or new uses can extend market exclusivity.
FAQs
1. What is the primary chemical or compound protected by CN1571659?
It encompasses a specific chemical entity, potentially a novel pharmaceutical compound with unique structural features, though precise chemical details require review of the patent document.
2. Can CN1571659 be used to block generic drug development in China?
Yes, during its active period, CN1571659 could prevent generic manufacturers from marketing similar formulations or methods that infringe its claims.
3. How does the expiry of CN1571659 affect market competition?
The expiration opens the Chinese market for generic equivalents, increasing competition but also offering opportunities for new formulations or improved derivatives.
4. Are there related patents that extend the protection of CN1571659 internationally?
Likely, applicants filed corresponding international patents through PCT or direct applications, but verification requires detailed patent family research.
5. How should companies navigate the patent landscape surrounding CN1571659?
Conduct comprehensive freedom-to-operate analyses, monitor ongoing patent applications, and consider strategic patenting of improvements or new indications to maintain competitive edge.
References
- Chinese Patent CN1571659. (Filing date: 2001).
- State Intellectual Property Office of China (SIPO). Patent Status Records.
- WIPO PatentScope Database.
- Patent Landscape Reports for Pharmaceutical Patents in China.
